A medical graduate from Laval University in 1968, then trained in internal medicine at McGill University and in microbiology / infectious diseases at Tufts University and the Massachusetts Institute of Technology in Boston, Dr. Michel G. Bergeron is a professor in the Department. of microbiology-infectiology and immunology of the Faculty of Medicine.

In 1974, he founded the Infectious Disease Research Centre (CRI) at Laval University, of which he was the director until recently. He played a major role in the introduction of infectious diseases research in Canada. Being a visionary, innovator and entrepreneur, he assembled a transdisciplinary team of more than 200 researchers at the CRI, which makes it a North American centre of excellence for basic and applied research on HIV / AIDS, viral and bacterial respiratory infections, microbial resistance, tropical diseases (leishmaniasis and malaria), hospital infections, rapid molecular diagnosis (at the point-of-care), the prevention of sexually transmitted infections and vaccinology, all of which is supported by an arsenal of genomics , bioinformatics, and proteomics tools.

As an internationally renowned researcher and the author of over 400 publications, 600 scientific presentations, and 30 patents, Dr. Bergeron has trained more than 80 graduate students and postdoctoral fellows. He and his team revolutionized the diagnosis of infections by creating fast, innovative, DNA-based assays that enable rapid and specific identification of microbes responsible for severe infections, as well as their resistance genes, in less than one hour instead of the 2-3 days required by conventional culture methods. Several tests designed at the CRI were transferred and developed by Infectio Diagnostic (IDI) Inc., a company he founded in 1995, prior to being approved by the FDA. Since 2006, these tests are sold in 50 countries by Becton Dickinson, a company established in the Metropolitan Quebec Technology Park that employs more than 300 people in its production and R&D centres, following investments of over $800 million in the region. These tests, which promote the appropriate use of antibiotics, save lives and limit the spread of infections as well as their resistance to antibiotics.

Lately, Dr. Bergeron has been bringing the lab closer to patients with his new generation of fast, easy-to-use, molecular diagnostic instruments and tests at the point-of-care he calls the “Nespresso of Diagnostics”. These are now sold by GenePOC, a company he founded that employs more than 100 people. Due to his exceptional professional achievements, Dr. Bergeron received, among others, in 2005 the “Wilder-Penfield” Quebec Award. He was invested as an Officer of the National Order of Quebec in 2008, and then as a Member of the Order of Canada in 2011. He received the Ernest C. Manning Innovation main Award in 2016, prior to being inducted into the Canadian Medical Hall of Fame in 2017. The scientific and socio-economic impact of his discoveries is considerable.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2
373 entries « 38 of 38 »

Brusch JL, Barza M, Bergeron MG, Weinstein L

Cross-resistance of Pseudomonas to gentamicin and tobramycin.

Journal Article

Antimicrob Agents Chemother, 1 (3), pp. 280-1, 1972, ISSN: 0066-4804.

| Links:

Bergeron MG

[Application of the Giordano-Giovannetti diet to 23 patients with advanced kidney failure]

Journal Article

Laval Med, 41 (3), pp. 340-4, 1970, ISSN: 0023-9046.

| Links:

Bergeron MG

Immunité des maladies à virus

Journal Article

Laënnec médical, (4), pp. 13-17, 1967.

373 entries « 38 of 38 »
Signaler des ajouts ou des modifications

Active projects

  • 3.6 The gut microbiome: sentinel of the northern environment and Inuit mental health, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds d'excellence en recherche Apogée Canada, from 2017-04-01 to 2020-03-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2020-04-30
  • Programme chercheur-e d'un jour, Subvention, Fonds de recherche du Québec - Société et culture, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Expanding the molecular point-of-care test menu with two gram-positive cocci, Partenariat, Génome Canada, Programme de partenariats pour les applications de la génomique (PPAG), from 2015-09-25 to 2019-03-31
  • Programme Chercheur d'un jour, Subvention, Conseil de recherches en sciences naturelles et génie Canada, PromoScience, from 2018-01-01 to 2018-12-31
Data provided by the Université Laval research projects registery